 |
 |
 |
 |
 |
According to the FAB group (Bennett JM, et al, J. Clin. Pathol. 1989;
42:567-584), the incidence at which FMC7 is positive in >30% of cells in
intermediate lymphocytic lymphoma (ie, Mantle Cell lymphoma) is 40-80%; in
CLL, it is 10-40%.
Our lab here in Scottsdale does not use FMC7; our panel resembles what Hugh
Johnson has listed in his message earlier. We found that the addition of CD23
sometime ago has facilitated identification of early (leukemic) presentations
of MCL (CD5+/CD23-). These cases probably account for as many as 5-10% of our
clonal B cell lymphoid leukemia patients. I would, however, add something to
what Maryalice and Hugh have stated: the relative *intensity* of sIg and CD20
expression can be extremely helpful in distinguishing between MCL and CLL. MCL
(and other NHL) are typically bright CD20+ and bright kappa (or lambda)
positive, while CLL shows dim/weak expression for these markers.
What do some other folks have to say about panels in the workup of chronic
lymphoid leukemias? (Randy Gascoyne? Curt Hanson?)
***************************************************************
Christopher R. Conley, MD conley.christopher@mayo.edu
Dept. of Pathology Tel:(602)301-8021 FAX:(602)301-8372
Mayo Clinic Scottsdale 13400 E. Shea Blvd. Scottsdale AZ 85259
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web